Feline Transitional Cell Carcinoma (Urinary Bladder Neoplasia)

Feline transitional cell carcinoma (TCC) of the urinary bladder is a malignant epithelial neoplasm arising from the urothelium lining the lower urinary tract in cats. It is considered a rare condition, with an estimated prevalence of approximately 0.18% in the feline population [2]. Despite its rarity, TCC carries significant clinical importance because its signs closely mimic far more common disorders such as feline idiopathic cystitis (FIC) and bacterial urinary tract infections, leading to frequent diagnostic delays [2, 3]. Notably, a strikingly high prevalence of TCC has also been documented in captive fishing cats (Prionailurus viverrinus), suggesting a possible hereditary or species-specific predisposition in certain felid lineages [4, 5, 8].

Tumor Origin and Histopathology

Transitional cell carcinoma (also known as urothelial carcinoma) originates from the transitional epithelium (urothelium) lining the urinary bladder and, less commonly, the urethra and ureters. The tumor is typically invasive, infiltrating into the submucosa and muscular layers of the bladder wall, and can spread to regional lymph nodes and distant organs [1, 3].

Molecular and Biochemical Pathways

Studies in fishing cats have shed light on potential molecular mechanisms relevant to feline TCC. Expression of cyclooxygenase-2 (COX-2) has been detected in TCC tissue, paralleling findings in canine and human urothelial carcinoma; COX-1 expression was also identified but was less consistently associated with malignant transformation [4]. Overexpression or altered expression of the tumor suppressor protein p53 was detected immunohistochemically in fishing cat TCC cases, suggesting that disruption of normal apoptotic and cell-cycle regulation pathways contributes to urothelial carcinogenesis [4]. These findings parallel pathways well-characterized in canine TCC, providing a biological rationale for exploring COX-inhibitor-based therapy in cats.

Genetic and Hereditary Considerations

A genomic investigation using a chromosome-scale reference genome for fishing cats identified a high prevalence of TCC within the zoo-managed population and explored germline risk variants that may underlie heritable susceptibility [5]. Pedigree analysis confirmed familial clustering, supporting a hereditary component in this species [5, 8]. While a comparable genetic study has not yet been completed in domestic cats, the clustering of TCC in certain feline species raises the possibility of genetic predisposing factors in domestic cats as well.

Epidemiological Risk Factors

In domestic cats, no single definitively proven environmental carcinogen has been identified as in dogs (where exposure to certain pesticides and insecticides is strongly implicated). The rarity of the disease in cats means that large-scale epidemiological risk factor analyses are limited. Domestic shorthair cats appear to be the most commonly affected breed, likely reflecting their population prevalence rather than a true breed predisposition [1, 3]. Older cats are disproportionately affected, consistent with the cumulative mutagenic insults underlying most carcinomas [1, 3].

Clinical Suspicion

Diagnosis begins with clinical suspicion in any cat presenting with chronic, recurrent, or refractory lower urinary tract signs — particularly hematuria, stranguria, or pollakiuria that fails to respond to appropriate therapy for FIC or urinary tract infection [2, 3]. A high index of suspicion is essential given the symptom overlap with benign conditions.

Ultrasonography

Ultrasonography of the urinary bladder is the primary imaging modality for initial evaluation. Feline TCC shares ultrasonographic characteristics with canine TCC [2]. Typical findings include:

• ·An irregular, polypoid, or sessile mass projecting into the bladder lumen
• ·Thickening of the bladder wall, often with loss of normal layered architecture
• ·Masses may arise from the trigone (as in dogs), or from other bladder regions
• ·Ureteral or urethral involvement may be identified, and hydronephrosis may be detected if ureteral obstruction is present [2, 7]

A multicenter retrospective study specifically characterized the ultrasound findings of feline TCC, confirming that feline and canine TCC share similar sonographic features, which enables application of established canine imaging criteria to feline patients [2].

Cytology and Histopathology

Definitive diagnosis requires histopathological confirmation. Tissue can be obtained via:

• ·Traumatic catheterization or bladder wash cytology (useful but with variable sensitivity)
• ·Ultrasound-guided fine-needle aspirate (cytology) — may yield a presumptive diagnosis, though atypical urothelial cells can also be seen in inflammatory conditions
• ·Cystoscopic biopsy — allows direct visualization and targeted sampling
• ·Surgical biopsy or cystotomy — provides the most definitive tissue sample [3, 6]

Histopathology remains the gold standard, with TCC characterized by invasive nests and cords of pleomorphic transitional epithelial cells with variable degrees of differentiation [3, 4].

Computed Tomography (CT)

Contrast CT is increasingly used to characterize mass extent, assess regional lymph node involvement, identify ureteral obstruction, and stage the disease prior to surgical or palliative intervention [6, 7]. CT provides superior anatomical detail compared to ultrasound alone and is particularly valuable for surgical planning.

Laboratory Findings

While no laboratory test is pathognomonic for TCC, the following clinicopathological findings may be present and warrant evaluation:

• ·Urinalysis: Hematuria (RBCs on sediment), proteinuria, and possibly abnormal/atypical epithelial cells on urine sediment examination; concurrent bacterial urinary tract infection is common
• ·Complete blood count (CBC):
  • ·Anemia (low HCT/PCV): May develop secondary to chronic hematuria or chronic disease; a low-grade non-regenerative anemia of chronic disease may be present
  • ·Leukocytosis (high WBC): May be present if concurrent urinary tract infection or paraneoplastic inflammation is present
  • ·Thrombocytosis or thrombocytopenia (PLT): Variable; not a consistent or specific finding
• ·Serum biochemistry:
  • ·BUN and CREA (elevated): Azotemia may develop secondary to urinary outflow obstruction, hydroureter, or hydronephrosis; renal insufficiency secondary to obstructive uropathy is a serious complication [7]
  • ·ALT: Generally within normal limits unless hepatic metastasis occurs in advanced disease
  • ·ALB (albumin): May be low in advanced malignancy due to cachexia and chronic disease
  • ·GLOB (globulins): May be elevated due to chronic inflammatory response
  • ·TBIL: Typically normal unless end-stage or hepatic involvement

Thoracic radiographs should be evaluated to assess for pulmonary metastasis, and abdominal imaging used to evaluate sublumbar lymph nodes.

General Principles

Because feline TCC is often locally advanced at diagnosis and carries significant surgical complexity — particularly when the trigone is involved — treatment is frequently palliative rather than curative. A multimodal approach combining surgery, medical therapy, and supportive care offers the best outcomes [1, 3].

Surgical Intervention

Partial cystectomy has been employed when tumor location and extent permit adequate resection margins. However, trigone involvement (common in both canine and feline TCC) often precludes complete surgical excision without sacrifice of ureteral and urethral orifices [1, 3].

Total cystectomy with urinary diversion represents a more radical option explored in select cases. A modified Toyoda technique for total cystectomy combined with bilateral cutaneous ureterostomy has been described in a cat with TCC, demonstrating technical feasibility of this approach even in a 16-year-old patient [6]. While technically challenging, this approach may be considered when less aggressive surgery is not curative and the patient's overall health permits [6].

Cystotomy and biopsy have been performed in fishing cats primarily as diagnostic procedures [8].

Interventional / Palliative Procedures

For cats with malignant urinary outflow obstruction due to TCC — including ureteral and/or urethral obstruction — minimally invasive interventional procedures offer meaningful palliation:

• ·Subcutaneous ureteral bypass (SUB) device: Used to relieve ureteral obstruction secondary to TCC-related compression or infiltration
• ·Transurethral self-expanding metallic stents (SEMS): Used to palliate urethral obstruction and restore urinary flow

A retrospective study of 14 cats with malignant urinary outflow obstructions treated with SUB devices and/or SEMS reported technical success in restoring urinary drainage, with meaningful improvement in quality of life despite the underlying malignancy [7]. This approach represents an important palliative option for cats that are not surgical candidates for definitive resection [7].

Medical (Pharmacological) Therapy

NSAIDs / COX inhibitors: Given the expression of COX-2 in feline TCC (paralleling canine TCC), piroxicam and meloxicam have been used as part of medical management, similar to protocols established in dogs [1, 4]. These agents may have both palliative (anti-inflammatory) and potential antitumor effects via COX-2 inhibition, though robust prospective efficacy data specific to cats are limited.

Chemotherapy: Various chemotherapy protocols have been reported in cats with TCC, including:

• ·Mitoxantrone: Used alone or in combination with piroxicam
• ·Carboplatin: Has been employed in feline urinary tract carcinomas
• ·Chlorambucil and other alkylating agents: Used in some protocols

In the largest case series of 118 cats with lower urinary tract TCC, various treatment modalities were examined including surgery, chemotherapy, NSAIDs, and combinations thereof [1]. Treatment selection was individualized based on tumor location, extent, and patient factors.

Supportive Care

• ·Management of concurrent urinary tract infections with appropriate antibiotics
• ·Fluid therapy and supportive care for cats with azotemia secondary to obstructive uropathy
• ·Nutritional support and management of cancer cachexia
• ·Pain management (opioids, gabapentin, or NSAIDs where appropriate)
• ·Monitoring of renal parameters (BUN, CREA) especially in cats receiving NSAIDs or with obstructive complications

Overall Prognosis

Feline TCC carries a guarded to poor prognosis. The disease is typically diagnosed at an advanced stage, metastatic spread is possible, and the proximity of tumors to the trigone frequently limits surgical curability [1, 3].

Survival Statistics from Key Studies

The largest and most comprehensive outcomes study to date — a multicenter retrospective review of 118 cats with lower urinary tract TCC — provides the most robust survival data available for this disease [1]:

• ·Median survival times varied by treatment modality, with some treatment combinations associated with longer survival than others [1]
• ·The study identified prognostic variables from clinical characteristics, treatments, and outcomes, underscoring that treatment type and disease extent at diagnosis are important determinants of outcome [1]

An earlier case series of 20 cats (1990–2004) also reported outcomes, noting that survival was generally short with medical management alone, and that cats with advanced disease at presentation had limited survival regardless of intervention [3].

Prognosis by Treatment Approach

• ·Cats treated with palliative interventional procedures (SUB device and/or urethral stenting) for malignant obstruction achieved restoration of urinary flow and improved quality of life, though long-term survival remained limited by the underlying malignancy [7]
• ·Cats undergoing total cystectomy with urinary diversion (a radical approach) may achieve longer disease-free intervals in selected cases, though this remains based on limited case report evidence [6]
• ·Medical management with NSAIDs +/- chemotherapy generally provides palliative benefit with modest survival extension

Fishing Cat TCC Mortality

In captive fishing cats (Prionailurus viverrinus), TCC is a leading cause of death: 13% of all adult deaths (12 of 91) between 1995 and 2004 were attributed to TCC, underscoring the severity of this disease in that population [4].

Important Limitations

Feline TCC is sufficiently rare that randomized controlled trials do not exist, and survival statistics are derived from retrospective case series with variable patient populations, diagnostic criteria, and treatments. Precise median survival times should be interpreted in this context. Overall, the prognosis for most cats diagnosed with lower urinary tract TCC remains guarded, with quality of life and palliation of obstructive symptoms being primary treatment goals in many cases.

Lack of Established Prevention Strategies

There are currently no vaccines or proven chemoprevention protocols for feline TCC. Because the specific environmental and genetic risk factors in domestic cats have not been fully characterized, targeted prevention recommendations remain limited.

General Considerations

• ·Regular veterinary monitoring: Older cats presenting with recurrent or refractory lower urinary tract signs should undergo prompt and thorough urinary tract evaluation, including ultrasonography, to enable earlier diagnosis
• ·Genetic screening (fishing cats): Given the documented hereditary predisposition in captive fishing cats, genomic screening tools — including the recently developed chromosome-scale reference genome for fishing cats — may aid in identifying at-risk individuals and informing breeding management decisions to reduce prevalence in zoo populations [5]
• ·Avoidance of known carcinogens: While specific environmental carcinogens have not been definitively proven in cats as they have in dogs (e.g., certain herbicides/insecticides linked to canine TCC), minimizing exposure to potential environmental mutagens represents a prudent general recommendation
• ·COX-2 pathway research: The documented expression of COX-2 in feline TCC [4] raises the theoretical possibility that long-term NSAID use could have chemopreventive properties, as has been explored in human colorectal cancer research, though this has not been studied prospectively in cats

In summary, current prevention is largely limited to early detection through owner awareness of warning signs, routine veterinary examination, and prompt evaluation of persistent urinary tract signs.